de Oliveira Aquino Fábio, da Silva Ricardo Eccard, Garbi Novaes Maria Rita Carvalho
Universidade de Brasília, Brasil.
Agência Nacional de Vigilância Sanitária, Brasil.
Concilium. 2024 Oct;24(19):126-144. Epub 2024 Sep 14.
Brazil is home to around 13 million rare disease patients, which represents a significant challenge for biomedical research and public health. This descriptive and exploratory study analyzed research protocols on rare diseases submitted to Plataforma Brasil between 2013 and 2023, with the aim of identifying trends, challenges and opportunities for scientific progress in this area. The research evaluated variables such as the number of studies submitted and approved, sample characteristics, type of study, experimental design, research phase, participation in international networks, and epidemiological data (ICD). The results indicate a substantial increase in the number of protocols submitted over the period analyzed, with an average approval rate of 87.26%. Most of the studies were conducted in public institutions, highlighting the fundamental role of the public sector in rare disease research in Brazil. These findings suggest a growing investment and interest in research in this area, which could boost the development of new therapies and interventions, as well as supporting the formulation of more effective public policies to meet the needs of patients with rare diseases.
巴西约有1300万罕见病患者,这对生物医学研究和公共卫生构成了重大挑战。这项描述性和探索性研究分析了2013年至2023年间提交给巴西平台(Plataforma Brasil)的罕见病研究方案,旨在确定该领域科学进展的趋势、挑战和机遇。该研究评估了诸如提交和批准的研究数量、样本特征、研究类型、实验设计、研究阶段、参与国际网络情况以及流行病学数据(国际疾病分类)等变量。结果表明,在所分析的时间段内提交的方案数量大幅增加,平均批准率为87.26%。大多数研究在公共机构进行,凸显了公共部门在巴西罕见病研究中的基础性作用。这些发现表明对该领域研究的投资和兴趣不断增加,这可能会推动新疗法和干预措施的开发,并有助于制定更有效的公共政策以满足罕见病患者的需求。